Bo Xu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Bo Xu has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
Aijuan Sun
Department of Pathology, Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi Medical Center of Nanjing Medical University, Wuxi People's Hospital, Wuxi, 214023, Jiangsu, China
1 shared publication- Chao Tang
Department of Gynecology
1 shared publication - Chunxi Wang
Department of Urinary , 117971 The First Hospital of Jilin University , Changchun , China
1 shared publication - Guangjun Hu
The first clinical college of Southern Medical University, Guangzhou 430060, Guangdong Province, China; Department of Anesthesiology, Wuhan third Hospital/Tongren Hospital of Wuhan University, Wuhan, Hubei Province, China; Department of Anesthesiology, General Hospital of the Southern Theater Command of the Chinese PLA, Guangzhou 510010, Guangdong Province, China
1 shared publication Hongyu Li
Department of Basic Medicine, Wuxi School of Medicine, Jiangnan University, Wuxi, 214122, Jiangsu, China
1 shared publicationJiawen Li
Department of Basic Medicine, Wuxi School of Medicine, Jiangnan University, Wuxi, 214122, Jiangsu, China
1 shared publication
Latest Publications
- 23 June 2026
- Published by Springer Nature in Lung
- Vol. 204 (1)
Salvinorin A Alleviates Bleomycin-Induced Pulmonary Fibrosis by Inhibiting M2 Macrophage Polarization and Macrophage-to-Myofibroblast Transition
Pulmonary fibrosis (PF) is a progressive and fatal interstitial lung disease with limited treatment options. Macrophages, as the primary immune cells in the lungs, play a key role in the progression of pulmonary fibrosis. Salvinorin A (SA), a naturally occurring non-nitrogenous diterpenoid, exhibits anti-inflammatory and anti-neuropathic pain effects in various models. However, whether SA alleviates bleomycin-induced pulmonary fibrosis by modulating macrophage function remains unclear. This study aimed to investigate the therapeutic effects and mechanisms of SA on bleomycin-induced pulmonary fibrosis in mice. A bleomycin-induced pulmonary fibrosis mouse model was established, and SA was administered via intraperitoneal injection starting from day 7 post-modeling. The study further explored the effects of SA on M2 macrophage polarization and macrophage-to-myofibroblast transition (MMT) both in vivo and in vitro. SA treatment significantly alleviated the degree of pulmonary fibrosis and inflammatory response, improved lung tissue pathological structure, and reduced extracellular matrix deposition and the release of related inflammatory cytokines. Mechanistic studies revealed that SA effectively inhibited M2 macrophage polarization both in vivo and in vitro, as evidenced by the downregulation of marker molecules such as CD206, Arg1, Fizz1, and YM1. Additionally, SA also inhibited MMT, specifically manifested as a significant decrease in the proportion of α-SMA⁺CD68⁺ double-positive cells. This study reveals that SA can effectively alleviate the progression of pulmonary fibrosis by dually inhibiting M2 macrophage polarization and the MMT process, providing important experimental evidence for SA as a potential therapeutic agent against pulmonary fibrosis.
- 23 June 2026
- Published by Springer Nature in Lung
- Vol. 204 (1)
Salvinorin A Alleviates Bleomycin-Induced Pulmonary Fibrosis by Inhibiting M2 Macrophage Polarization and Macrophage-to-Myofibroblast Transition
Pulmonary fibrosis (PF) is a progressive and fatal interstitial lung disease with limited treatment options. Macrophages, as the primary immune cells in the lungs, play a key role in the progression of pulmonary fibrosis. Salvinorin A (SA), a naturally occurring non-nitrogenous diterpenoid, exhibits anti-inflammatory and anti-neuropathic pain effects in various models. However, whether SA alleviates bleomycin-induced pulmonary fibrosis by modulating macrophage function remains unclear. This study aimed to investigate the therapeutic effects and mechanisms of SA on bleomycin-induced pulmonary fibrosis in mice. A bleomycin-induced pulmonary fibrosis mouse model was established, and SA was administered via intraperitoneal injection starting from day 7 post-modeling. The study further explored the effects of SA on M2 macrophage polarization and macrophage-to-myofibroblast transition (MMT) both in vivo and in vitro. SA treatment significantly alleviated the degree of pulmonary fibrosis and inflammatory response, improved lung tissue pathological structure, and reduced extracellular matrix deposition and the release of related inflammatory cytokines. Mechanistic studies revealed that SA effectively inhibited M2 macrophage polarization both in vivo and in vitro, as evidenced by the downregulation of marker molecules such as CD206, Arg1, Fizz1, and YM1. Additionally, SA also inhibited MMT, specifically manifested as a significant decrease in the proportion of α-SMA⁺CD68⁺ double-positive cells. This study reveals that SA can effectively alleviate the progression of pulmonary fibrosis by dually inhibiting M2 macrophage polarization and the MMT process, providing important experimental evidence for SA as a potential therapeutic agent against pulmonary fibrosis.
- 1 January 2022
- Published by Elsevier in Brain Research Bulletin
- Vol. 178, 164-172
MicroRNA-214–5p involves in the protection effect of Dexmedetomidine against neurological injury in Alzheimer’s disease via targeting the suppressor of zest 12
- 1 January 2022
- Published by Elsevier in Brain Research Bulletin
- Vol. 178, 164-172
MicroRNA-214–5p involves in the protection effect of Dexmedetomidine against neurological injury in Alzheimer’s disease via targeting the suppressor of zest 12
- Open Access
- 18 August 2020
- Published by Spandidos Publications in Oncology Reports
- Vol. 44 (5) , 1939-1948
Andrographolide sensitizes human renal carcinoma cells to TRAIL‑induced apoptosis through upregulation of death receptor 4
Tumor necrosis factor‑related apoptosis‑inducing ligand (TRAIL) selectively induces apoptosis in cancer cells, with minimal toxicity to normal tissues. However, accumulating evidence suggests that certain cancer types are insensitive to TRAIL signaling. The aim of this study was to identify an effective combination regimen, which can overcome TRAIL resistance in renal cancer cell. Herein, we found that human renal carcinoma cells (RCCs) are widely resistant to TRAIL‑mediated growth inhibition and subsequently identified that andrographolide (Andro), a major constituent of Andrographis paniculate, an annual herbaceous plant in the family Acanthaceae, counteracts TRAIL resistance in RCCs. Combined treatment with TRAIL and Andro suppressed cell viability as determined by MTS and proliferation as determined by EdU in a dose‑dependent manner and inactivated the clonogenic and migration ability of RCCs. Andro significantly enhances TRAIL‑mediated cell cycle arrest at the G2/M phase as determined by flow cytometry and senescence. Moreover, Andro restored TRAIL signaling, which in turns activated pro‑apoptosis caspases as determined by immunoblot assay. The TRAIL receptor, death receptor (DR)4, but not DR5, was found to be significantly upregulated in Andro‑treated RCC cells, which contributed to the role of Andro as a TRAIL sensitizer. The present study demonstrated that the combined treatment of Andro and TRAIL has potential therapeutic value against renal cancer.
- 18 August 2020
- Published by Spandidos Publications in Oncology Reports
- Vol. 44 (5) , 1939-1948
Open AccessAndrographolide sensitizes human renal carcinoma cells to TRAIL‑induced apoptosis through upregulation of death receptor 4
Tumor necrosis factor‑related apoptosis‑inducing ligand (TRAIL) selectively induces apoptosis in cancer cells, with minimal toxicity to normal tissues. However, accumulating evidence suggests that certain cancer types are insensitive to TRAIL signaling. The aim of this study was to identify an effective combination regimen, which can overcome TRAIL resistance in renal cancer cell. Herein, we found that human renal carcinoma cells (RCCs) are widely resistant to TRAIL‑mediated growth inhibition and subsequently identified that andrographolide (Andro), a major constituent of Andrographis paniculate, an annual herbaceous plant in the family Acanthaceae, counteracts TRAIL resistance in RCCs. Combined treatment with TRAIL and Andro suppressed cell viability as determined by MTS and proliferation as determined by EdU in a dose‑dependent manner and inactivated the clonogenic and migration ability of RCCs. Andro significantly enhances TRAIL‑mediated cell cycle arrest at the G2/M phase as determined by flow cytometry and senescence. Moreover, Andro restored TRAIL signaling, which in turns activated pro‑apoptosis caspases as determined by immunoblot assay. The TRAIL receptor, death receptor (DR)4, but not DR5, was found to be significantly upregulated in Andro‑treated RCC cells, which contributed to the role of Andro as a TRAIL sensitizer. The present study demonstrated that the combined treatment of Andro and TRAIL has potential therapeutic value against renal cancer.
- 2 March 2012
- Published by Taylor & Francis in Drug and Chemical Toxicology
- Vol. 36 (2) , 205-208
The toxic effect of opioid analgesics on human sperm motilityin vitro
Opioid analgesics are the most common therapeutic analgesic for acute pain. In this study, the toxicological and pharmacological features of a group of opioid analgesics were characterized by the motility of human sperm. Aliquots of sperm were incubated with various concentrations of opioid analgesics in vitro. Computer-assisted sperm analysis was used to assess sperm motility at 15 minutes, 2 hours, and 4 hours after drug addition to the medium. Butorphanol and dezocine showed marked reduction of motility after incubation with sperm for 15 minutes. Butorphanol was more effective than dezocine in immobilizing sperm. Other opioids studied, such as fentanyl, alfentanil, and sufentanil, showed only partial inhibitory activity. Based on the data reported herein, we have found that butorphanol and dezocine exert a sperm-immobilizing effect. However, fentanyl, alfentanil, and sufentanil exhibit only partial inhibition of sperm motility. Given the increasing use of opioids and their potential effect on sperm motility, these findings are greatly relevant to male reproductive health.
- 2 March 2012
- Published by Taylor & Francis in Drug and Chemical Toxicology
- Vol. 36 (2) , 205-208
The toxic effect of opioid analgesics on human sperm motilityin vitro
Opioid analgesics are the most common therapeutic analgesic for acute pain. In this study, the toxicological and pharmacological features of a group of opioid analgesics were characterized by the motility of human sperm. Aliquots of sperm were incubated with various concentrations of opioid analgesics in vitro. Computer-assisted sperm analysis was used to assess sperm motility at 15 minutes, 2 hours, and 4 hours after drug addition to the medium. Butorphanol and dezocine showed marked reduction of motility after incubation with sperm for 15 minutes. Butorphanol was more effective than dezocine in immobilizing sperm. Other opioids studied, such as fentanyl, alfentanil, and sufentanil, showed only partial inhibitory activity. Based on the data reported herein, we have found that butorphanol and dezocine exert a sperm-immobilizing effect. However, fentanyl, alfentanil, and sufentanil exhibit only partial inhibition of sperm motility. Given the increasing use of opioids and their potential effect on sperm motility, these findings are greatly relevant to male reproductive health.
- 1 March 2012
- Published by Wiley in Journal of Biochemical and Molecular Toxicology
- Vol. 26 (4) , 176-177
Remifentanil impairs sperm motility reversibly in vitro
The study is to observe the effects of remifentanil on human sperm motility in vitro. After spermatozoa were washed and resuspended in Ham's F-10 medium, the washed human sperm suspensions were treated in vitro with different concentrations of remifentanil for 30 min. Sperm motility was assessed by computer-assisted sperm analysis at 5, 10, 15, and 30 min. Remifentanil significantly decreased (a + b) grade spermatozoa, between 5 and 10 min at the concentrations ranging from 0.1 to 100 μg L - 1 in a dose-dependent manner and effects no significant difference at 15 and 30 min as compared with control groups. The results suggest that there is indication that this drug has short-term effect on sperm motility. © 2012 Wiley Periodicals, Inc. J Biochem Mol Toxicol 26:176–177, 2012; View this article online at wileyonlinelibrary.com. DOI 10.1002/jbt.21408
- 1 March 2012
- Published by Wiley in Journal of Biochemical and Molecular Toxicology
- Vol. 26 (4) , 176-177
Remifentanil impairs sperm motility reversibly in vitro
The study is to observe the effects of remifentanil on human sperm motility in vitro. After spermatozoa were washed and resuspended in Ham's F-10 medium, the washed human sperm suspensions were treated in vitro with different concentrations of remifentanil for 30 min. Sperm motility was assessed by computer-assisted sperm analysis at 5, 10, 15, and 30 min. Remifentanil significantly decreased (a + b) grade spermatozoa, between 5 and 10 min at the concentrations ranging from 0.1 to 100 μg L - 1 in a dose-dependent manner and effects no significant difference at 15 and 30 min as compared with control groups. The results suggest that there is indication that this drug has short-term effect on sperm motility. © 2012 Wiley Periodicals, Inc. J Biochem Mol Toxicol 26:176–177, 2012; View this article online at wileyonlinelibrary.com. DOI 10.1002/jbt.21408
- 1 October 2011
- Vol. 17 (10) , 926-9
[Effects of remifentanil combined with naloxone on human sperm motility].
To observe the effects of remifentanil combined with naloxone on human sperm motility in vitro and to investigate its possible mechanism. Twenty normal semen samples were collected, each divided into 13 aliquots, one as the control and the others treated in vitro with different concentrations of remifentanil or remifentanil + naloxone for 35 min. The percentage of progressive mobile sperm was assessed by computer-assisted sperm analysis at 5, 10, 15, 20 and 35 min. Compared with the control group, remifentanil at 0.1, 1, 10 and 100 microg/L significantly decreased sperm motility at 5 and 10 min in a dose-dependent manner, with no significant difference at 15 and 30 min; sperm motility showed no significant difference on 5 -35 min exposure to naloxone at 0.004 -0.04 mg/L, nor on 5, 10, 15 and 20 min exposure at 0.4 -4 mg/L, but was significantly increased at 35 min. Compared with the corresponding concentrations of remifentanil alone, remifentanil + naloxone remarkably increased sperm motility at 0.1 + 0.004, 1 + 0.04, 10 + 0.4, and 100 + 4 mg/L at 5 and 10 min, with no obvious difference at 15 and 30 min. The onset and offset of the effect of remifentanil on sperm motility are rapid and its inhibitory effect can be antagonized by naloxone, which may be related with the micro-opioid receptor.
- 1 October 2011
- Vol. 17 (10) , 926-9
[Effects of remifentanil combined with naloxone on human sperm motility].
To observe the effects of remifentanil combined with naloxone on human sperm motility in vitro and to investigate its possible mechanism. Twenty normal semen samples were collected, each divided into 13 aliquots, one as the control and the others treated in vitro with different concentrations of remifentanil or remifentanil + naloxone for 35 min. The percentage of progressive mobile sperm was assessed by computer-assisted sperm analysis at 5, 10, 15, 20 and 35 min. Compared with the control group, remifentanil at 0.1, 1, 10 and 100 microg/L significantly decreased sperm motility at 5 and 10 min in a dose-dependent manner, with no significant difference at 15 and 30 min; sperm motility showed no significant difference on 5 -35 min exposure to naloxone at 0.004 -0.04 mg/L, nor on 5, 10, 15 and 20 min exposure at 0.4 -4 mg/L, but was significantly increased at 35 min. Compared with the corresponding concentrations of remifentanil alone, remifentanil + naloxone remarkably increased sperm motility at 0.1 + 0.004, 1 + 0.04, 10 + 0.4, and 100 + 4 mg/L at 5 and 10 min, with no obvious difference at 15 and 30 min. The onset and offset of the effect of remifentanil on sperm motility are rapid and its inhibitory effect can be antagonized by naloxone, which may be related with the micro-opioid receptor.